Settlement amounts in the testosterone therapy MDL vary significantly by injury severity, causation evidence quality, and which defendant your case is against. AbbVie — the largest defendant and maker of AndroGel — reportedly settled its global MDL inventory for an amount estimated by plaintiffs' attorneys at $250 million to $500 million total (specific terms are confidential). Individual plaintiff shares within that settlement reflected injury type and case strength.

Bellwether trials tested the full range of case values: the first bellwether yielded $150,000 for a DVT plaintiff; a 2018 bellwether produced a $140 million punitive award (later reversed and substantially reduced on appeal). These verdicts — both wins and losses — established the range of outcomes and informed global settlement negotiations. Cases involving Eli Lilly (Axiron) and Actavis/Teva (Androderm) remain in active settlement discussions.